CDKN2A and sarcoma: In regards to the prognostic impact of CDKN2A loss in sarcoma, previous work had suggested that its loss might have prognostic significance in Ewing’s sarcoma [24–26], however, a large analysis of 568 Ewing’s patients enrolled on a Children’s Oncology Group (COG) protocol, failed to reproduce this finding [27].